Company intelligence / Profile preview

Chiesi Farmaceutici S.p.A.

Parma, Emilia-Romagna, Italypmc.ncbi.nlm.nih.gov ↗

Ownership: Private
Employees: ~6500
Development stage: Commercial

Overview

Chiesi has a diverse portfolio of marketed products across respiratory, neonatology, and rare disease areas. They have achieved European marketing authorization for velmanase alfa for alfa-mannosidosis and have stem cell treatments for limbal stem cell deficiency.

Therapeutic areas: PulmonologyRare DiseasesCardiovascular
Modalities: Small moleculesbiotechnology products (proteins)advanced therapeutics (gene and cell therapy)enzyme replacement therapy
Industry: Pharma

Drug pipeline

61 assets

beclometasone

Approved

60 more assets in the full pipeline.

Request access →

Partnerships

Kamada (inhaled alpha 1 antitrypsin)uniQure (gene therapy)Holostem (tissue-regeneration)Veloxis (immunosuppressant tacrolimus)Zymenex (acquisition)

Beyond the preview

Go deeper on Chiesi Farmaceutici S.p.A..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Chiesi Farmaceutici S.p.A..

Explore the full profile